PHASE-II EVALUATION OF MITOXANTRONE PLUS CISPLATINUM IN PATIENTS WITH ADVANCED BREAST-CANCER - A SOUTHWEST-ONCOLOGY-GROUP STUDY

被引：5

作者：

ATIBA, JO

GREEN, SJ

HYNES, HE

OSBORNE, CK

MILLER, TP

DAVIDNER, M

机构：

[1] UNIV CALIF IRVINE,COLL MED,IRVINE,CA 92717

[2] SW ONCOL GRP,CTR STAT,SEATTLE,WA

[3] WICHITA CCOP,WICHITA,KS

[4] UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX

[5] UNIV ARIZONA,ARIZONA CANC CTR,TUCSON,AZ 85724

[6] KANSAS CITY CLIN ONCOL PROGRAM,KANSAS CITY,MO

来源：

INVESTIGATIONAL NEW DRUGS | 1994年 / 12卷 / 02期

关键词：

CISPLATINUM; MITOXANTRONE; BREAST CANCER; PHASE I-II TRIAL;

D O I：

10.1007/BF00874442

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The Southwest Oncology Group studied the response rate and toxicity of mitoxantrone (7.5 or 10 mg/m(2) to 12.0 mg/m(2)) and cis-platinum (100 mg/m(2)) in 30 patients with advanced breast cancer as second-line therapy. There were 2 partial responses in 29 eligible patients. Toxicity was considerable, with 27 patients having grade 3 or 4 toxicity. Grade 3-4 toxicity included vomiting, thrombocytopenia, granulocytopenia, leukopenia and anemia. The combination of mitoxantrone plus cis-platinum has minimal activity as second-line therapy in metastatic breast cancer.

引用

页码：129 / 132

页数：4

共 9 条

[1] RANDOMIZED TRIAL OF DOXORUBICIN, BISANTRENE, AND MITOXANTRONE IN ADVANCED BREAST-CANCER - A SOUTHWEST-ONCOLOGY-GROUP STUDY
COWAN, JD
NEIDHART, J
MCCLURE, S
COLTMAN, CA
GUMBART, C
MARTINO, S
HUTCHINS, LF
STEPHENS, RL
VAUGHAN, CB
OSBORNE, CK
[J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (15): : 1077 - 1084
[2] CLINICAL SAFETY AND TOLERANCE OF MITOXANTRONE (NOVANTRONE)
CROSSLEY, RJ
[J]. CANCER TREATMENT REVIEWS, 1983, 10 : 29 - 36
[3] FORASTIERE HA, 1983, AM J CLIN ONCOL-CANC, V5, P243
[4] PHASE-II CLINICAL-TRIAL OF CIS-DICHLORODIAMMINE PLATINUM (CIS-DDP) FOR ANTITUMORIGENIC ACTIVITY IN PREVIOUSLY UNTREATED PATIENTS WITH METASTATIC BREAST-CANCER
KOLARIC, K
ROTH, A
[J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1983, 11 (02) : 108 - 112
[5] MITOXANTRONE AS 1ST LINE CYTO-TOXIC THERAPY IN ADVANCED BREAST-CANCER - PRELIMINARY-RESULTS OF A PHASE-II STUDY
MOURIDSEN, HT
ROSE, C
NOOY, MA
VANOOSTEROM, AT
[J]. CANCER TREATMENT REVIEWS, 1983, 10 : 47 - 52
[6] MITOXANTRONE VERSUS DOXORUBICIN IN ADVANCED BREAST-CANCER - A RANDOMIZED CROSSOVER TRIAL
NEIDHART, JA
GOCHNOUR, D
ROACH, RW
STEINBERG, JA
YOUNG, D
[J]. CANCER TREATMENT REVIEWS, 1983, 10 : 41 - 46
[7] THERAPEUTIC ACTIVITY OF MITOXANTRONE AND AMETANTRONE AGAINST MURINE TUMORS
SCHABEL, FM
CORBETT, TH
GRISWOLD, DP
LASTER, WR
TRADER, MW
[J]. CANCER TREATMENT REVIEWS, 1983, 10 : 13 - 21
[8] SLEDGE GW, 1989, SEMIN ONCOL, V16, P110
[9] MITOXANTRONE (NOVANTRONE) AS SINGLE AGENT AND IN COMBINATION CHEMOTHERAPY IN THE TREATMENT OF ADVANCED BREAST-CANCER
SMITH, IE
STUARTHARRIS, R
PAVLIDIS, N
BOZEK, T
[J]. CANCER TREATMENT REVIEWS, 1983, 10 : 37 - 40

← 1 →